logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics - PDMR Dealing

RNS Number : 6252M
Silence Therapeutics PLC
12 May 2020
 

PDMR Dealing

May 12, 2020

 

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces the following share trades by Dr. Rob Quinn, Chief Financial Officer of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Rob Quinn

 

2.

Reason for the notification

a)

Position / status

Chief Financial Officer

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

 

b)

LEI

213800SSURRJBX85SQ91

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares in Silence Therapeutics plc

 

 

 

ISIN for Silence Therapeutics plc Ordinary Shares:

GB00B9GTXM62

 

b)

Nature of the transaction

Sale of Ordinary Shares in Silence Therapeutics plc

 

c)

Prices(a) and volume(s)

 

Price

Volume

£4.2921

15,942

£3.9804

73,112

 

 

d)

Aggregated information

- Aggregated volume

- Price

89,054 Ordinary Shares

£4.04

e)

Date of the transaction

7 and 11 May 2020

f)

Place of the transaction

London Stock Exchange, AIM

 

 

 

 

 

 

 

Enquiries:

 

Silence Therapeutics plc

Iain Ross, Executive Chairman

Dr Rob Quinn, Chief Financial Officer

Tel:  +44 (0)20 3457 6900

 

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

 

Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 

 Tel: +1 (443) 213-0505

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHKKBBBFBKKFPD

Quick facts: Silence Therapeutics PLC

Price: 464

Market: AIM
Market Cap: £384.31 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics feels move to NASDAQ will give its tech the...

Silence Therapeutics PLC's (LON:SLN) chairman Iain Ross and CFO Rob Quinn speak to Proactive London's Andrew Scott after announcing its intention to list on the American growth market, Nasdaq. Ross says in the US, RNAi is very hot at the moment and if you look at their competitor companies...

on 22/5/20